
    
      Identify biomarkers that can be used for evaluation of efficacy in subjects presenting with
      AECOPD by evaluating longitudinal changes and the interrelationship of blood and sputum
      biomarkers with physiological endpoints and symptom measures in stable subjects with COPD
      likely to experience a future AECOPD, and in subjects during severe AECOPD.
    
  